PCT-1 Throat Spray

About PridCor Therapeutics

PridCor Therapeutics is a private, pre-revenue biotech startup leveraging decades of founder experience to tackle poorly understood chronic illnesses. Its core strategy involves a fixed-dose combination therapy designed to suppress latent viral reactivation and reduce inflammation, initially targeting Long COVID. The company is also developing a proprietary throat spray for pharyngitis and a 3D-printed surgical device, positioning itself at the intersection of drug repurposing and specialized medical technology. A key clinical collaboration with Mount Sinai Hospital aims to validate its lead therapeutic approach.

Therapeutic Areas